Article Details
Retrieved on: 2021-04-19 19:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Aytu BioPharma has acquired the option to license DB102 (enzastaurin), an investigational anti-tumor therapy with the potential to treat vascular ...
Article found on: ehlersdanlosnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here